A Phase II study of Glypican-3(GPC3) peptide vaccine as adjuvant treatment for Hepatocellular carcinoma(HCC) after Surgical resection or Radiofrequency ablation(RFA)

Phase 2

• Conditions: Hepatocellular carcinoma(HCC)

• Registration Number: JPRN-UMIN000002614
• Lead Sponsor: Division of Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-10-11
• Study Completion: 2014-10-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1.Evident invasion to the portal vein, hepatic vein, or bile duct 2.Uncontrolled pleural effusion or ascites 3.There are other malignancies 4.Active infection excluding HBV, HCV 5.Clinically significant heart disease (myocardial infarction or unstable angina within the past six months, or uncontrolled cardiac arrhythmias) 6.There are severe complications including cardiac failure, renal failure, liver failure, active gastro-duodenal ulcer, ileus, and uncontrolled Diabetes Mellitus 7.There is severe psychiatric disorder 8.Pregnant or lactating woman, who are willing to be pregnant 9.Past history of severe drug allergy 10.Responsible doctors judged the patient in appropriate for the trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified